As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

As­traZeneca says its add-on pill for a rare blood dis­or­der known as parox­ys­mal noc­tur­nal he­mo­glo­bin­uria, or PNH, helped pa­tients al­ready tak­ing Ul­tomiris or Soliris pro­duce more he­mo­glo­bin than ei­ther ap­proved drug alone.

In an in­ter­im cut of da­ta of the AL­PHA study, 63 pa­tients with PNH who ex­pe­ri­ence symp­toms re­lat­ed to ex­travas­cu­lar he­mol­y­sis — when blood cells are de­stroyed out­side blood ves­sels — saw their he­mo­glo­bin lev­els in­crease by an av­er­age of 2.94 g/dL on dan­i­co­pan and ei­ther Ul­tomiris or Soliris com­pared to 0.50 g/dL in those pa­tients tak­ing Ul­tomiris or Soliris and place­bo at 12 weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER